- Details
- In this UroToday Journal Club video presentation Drs Christopher Wallis and Zachary Klaassen highlight a Lancet publication titled The Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy, the NRG RTOG 0534 SPPORT trial, an international, multicenter, randomized Phase III trial which was designed to determine whether incremental gains in pat...
|
- Details
- In this UroToday Journal Club presentation, Christopher Wallis and Zachary Klaassen highlight a JAMA Oncology publication led by Alex Bryant and Brent Rose titled The Association of PSA Screening Rates with Subsequent Metastatic Prostate Cancer Incidents at US Veterans Health Administration Facilities. PSA Screening is relatively controversial. Adopted in the United States in the 1990s it was asso...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the Journal of Nuclear Medicine publication entitled "mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in Post Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis." In low and middle-income countries, the treatment of prostate cancer is challenging due to a relatively advanced presentation of disease due to a lack of regu...
|
- Details
- In this UroToday Journal Club video presentation Christopher Wallis and Zachary Klaassen highlight the extended follow-up of overall survival and updated efficacy and safety in the CheckMate 9ER trial. The primary analysis of CheckMate 9ER showed nivolumab plus cabozantinib had superior progression-free survival, overall survival, and objective response over sunitinib in patients with previously u...
|
- Details
- Christopher Wallis and Zach Klaassen delve into the EV-201 study. This phase 2 trial investigates the efficacy of enfortumab vedotin in treating cisplatin-ineligible patients with advanced urothelial carcinoma who have previously received PD-1 or PD-L1 inhibitors. The study, conducted across 59 sites in North America, Europe, and Asia, shows a promising objective response rate of 52%, with 20% of...
|
- Details
- In this UroToday Journal Club, Christopher Wallis and Zachary Klaassen highlight the Journal of Nuclear Medicine publication titled The PRIMARY Score: Using intra-prostatic PSMA PET/CT patterns to optimise prostate cancer diagnosis. In this posthoc analysis the PRIMARY study evaluated the clinical significance of patterns of intra-prostatic PSMA activity, proposing a 5- point PRIMARY score to opti...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the publication entitled "Trends in Incidence of Metastatic Prostate Cancer in the US." Analysis of the emerging trends suggests that the incidence rates of metastatic prostate cancer have increased significantly and coincide temporally with the US Preventive Services Task Force (USPSTF) recommendations against prostate cancer screening across races...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss the Annals of Oncology article titled “Cabazitaxel versus abiraterone or enzalutamide in poor prognosis metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2 trial.” The goal of this publication was to determine the optimal treatment for poor prognosis metastatic castration-resistant prostate cancer (mCRPC) p...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a publication on the activity and adverse effects of Actinium-225 therapy, in advanced metastatic castrate resistant prostate cancer (mCRPC) patients, after the failure of their Lutetium-177 treatment. Dr. Wallis begins by discussing the topic of theranostics, and the difference between the beta-emitter, 177-Lutetium, and the alpha-emitter, 225-Actin...
|
- Details
- Christopher Wallis and Zachary Klaassen discuss a recent paper entitled, “UpFront PSMA: A Randomized Phase II Study of Sequential 177Lu-PSMA-617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naïve Prostate Cancer, a Clinical Trial Protocol.” Biographies: Christopher J.D. Wallis, MD, Ph.D., Assistant Professor in the Division of Urology at the University of Toronto Zachary Klaassen, MD, MSc,...
|